nificantly upregulated in HD cells and mouse brown fat by physiologically relevant stimuli that are known to upregulate PGC1 ␣ gene expression. This resulted in an increase in mitochondrial gene expression and cytochrome c content. Conclusion: Our data suggest that NT-PGC1 ␣ is an important component of the PGC1 ␣ transcriptional network, which plays a significant role in the pathogenesis of HD.
Huntington's disease (HD) is a progressive neurological disorder caused by a mutation in the huntingtin gene resulting in an expanded polyglutamine repeat within exon 1 [1] . Aberrant transcriptional regulation, oxidative stress, and dysregulation of mitochondrial energy metabolism have been implicated in the pathogenesis of HD [2] [3] [4] . Recent findings [5, 6] suggest that mutant huntingtin may disrupt normal mitochondrial function by inhibiting the expression of peroxisome proliferator-activated receptor-␥ coactivator 1 ␣ (PGC1 ␣ ), a transcriptional coactivator that has been shown to regulate the expression of nuclear-encoded mitochondrial proteins. cAMP signaling is a key activator of PGC1 ␣ transcription in many tissues, promoting the binding of cAMP response ele- ment (CRE)-binding protein (CREB) or the activating transcription factor-2 to a conserved DNA response element in the PGC1 ␣ promoter. Mutant huntingtin occupies the PGC1 ␣ promoter region and represses CRE-mediated transcription of PGC1 ␣ , by interfering with the CREB/TAF4 transcriptional pathway, in the brains and cells of transgenic HD mice [5] . Reduced CRE-dependent transcription has been previously observed as an early abnormality in the pathogenesis of HD [7] [8] [9] . Moreover, it has been shown that cAMP levels are reduced in a striatal cell model of HD, i.e. STHdh Q111/Q111 cells [7] ; treatment of these cells with 8-bromo-cAMP significantly upregulated the activity of the PGC1 ␣ reporter [5] .
Several PGC1 ␣ splice variants have been reported which might arise from differential internal splicing and/ or alternative promoter usage [10] [11] [12] [13] . The role of these variants in the regulation of transcription remains to be elucidated [14] . Zhang et al. [13] suggested that a truncated form of PGC1 ␣ (NT-PGC1 ␣ ) may exhibit regulatory activity. This protein is produced by alternative 3 splicing between exons 6 and 7 that introduces an inframe stop codon into PGC1 ␣ mRNA. NT-PGC1 ␣ retains the N-terminal transcriptional activation and nuclear-receptor interacting domains but lacks all domains within 268-797 amino acids of the full-length protein.
NT-PGC1 ␣ produces a cell context-specific subset of responses that complement, overlap, or prolong the actions of PGC1 ␣ [13] .
Here, we report that the NT-PGC1 ␣ protein is the major variant of PGC1 ␣ that is severely altered in human HD brain and in mouse and cell models of HD. Stimulation of the expression of NT-PGC1 ␣ in HD cells results in upregulation of the expression of PGC1 ␣ -controlled mitochondrial genes. NT-PGC1 ␣ is responsive to cold stimuli (a well-established physiologic stimulus of PGC1 ␣ ) in brown adipose tissue (BAT). Thus, NT-PGC1 ␣ appears to be an important component of the PGC1 ␣ transcriptional network that may play a role in the pathogenesis of HD.
Animals and Methods

Transgenic Animals
The N171-18Q mice, N171-82Q mice, and R6/2 mice were from Jackson Labs. The N171 mice have the N-terminal fragment (171 amino acids) of human huntingtin and either 82 or 18 glutamines on a B6C3F1 background [15] . The R6/2 mice were created with a 1.9-kb human genomic fragment containing promoter sequences and exon 1 carrying expansions of approximately 130 CAG repeats on a CBA ! C57BL/6 background [16] . The animals were kept on a 12-hour light/dark cycle with food and water available ad libitum. All experiments were conducted in accordance with National Institutes of Health guidelines for animal research and were approved by the Weill Cornell Medical College Animal Care and Use Committee.
Striatal Cell Culture and Treatments
STHdh Q7/Q7 (Q7) and STHdh Q111/Q111 (Q111) cells, generated from striatal primordia of wild-type (WT) Hdh Q7/Q7 and homozygous mutant Hdh Q111/Q111 knock-in mouse embryos, respectively [17] , were a gift from Dr. Marcy E. MacDonald. The cells were cultured in DMEM (33 ° C, 5% CO 2 , 10% FBS, 1% antibiotic-antimycotic, and 400 g/ml G418) and treated with 10 M forskolin + 50 M 3-isobutyl-1-methylxanthine (IBMX) for 2 h.
Myoblast Cell Culture
Myoblasts were derived from muscle biopsies obtained from nondiseased subjects and HD patients (who gave their informed consent) and cultured as previously described [18] . Myoblasts were grown in HAM's F10 medium (GIBCO; Invitrogen, Carlsbad, Calif., USA) supplemented with 15% FBS (Invitrogen, San Diego, Calif., USA), 0.5 mg/ml bovine serum albumin, 4 ng/ml insulin, 10 ng/ml epidermal growth factor, 0.39 g/ml dexamethasone, 0.1 mg/ml streptomycin, and 100 U/ml penicillin.
Human Brain Samples
Human postmortem brain specimens from the putamen region (HD grade 2, n = 5; grade 3, n = 4, and grade 4, n = 2; mean age ϳ 63 years, range 53-75; age-matched nondiseased samples (n = 7), mean age ϳ 65 years, range 57-76) were generously provided by the New York Brain Bank at Columbia University, Taub Institute.
Cold Challenge WT and R6/2 mice were exposed to 4 ° C for 4 h [19] and then sacrificed by cervical dislocation; BAT was harvested and frozen immediately.
Gene Expression Analysis by RT-PCR
Striatal cells were scraped and total RNA was isolated using Trizol reagent (Invitrogen). Genomic DNA was removed using RNase-free DNase (Ambion) in RNA pellets resuspended in DEPC-treated water (Ambion). Total RNA purity and integrity was confirmed by a ND-1000 NanoDrop (NanoDrop Technologies) and a 2100 Bioanalyzer (Agilent), respectively, with average 260/280 ratios for all study samples ranging from 1.9 to 2.1 and average RNA integrity numbers ranging from 7.5 to 9.0. Equal amounts of RNA were diluted in nuclease-free water (Ambion) to a final concentration of 10 ng/ l and reverse transcribed using a RevertAid First Strand cDNA Synthesis Kit (Fermentas, USA). Real-time RT-PCR was performed using the ABI prism 7900 HT sequence detection system (Applied Biosystems, Foster City, Calif., USA) to detect changes in mRNA expression using various primer pairs ( table 1 ) at a final volume of 20 l. All qPCR plating was performed on ice. Expression of the gene cyclophilin B served as a control to normalize values. Thermal cycling conditions were 50 ° C for 2 min, 95 ° C for 10 min, and then 40 cycles of 95 ° C for 15 s and 60 ° C for 1 min. Relative expression was calculated using the ⌬ ⌬ Ct method.
Western Blot Human brain tissues, striatum of WT and HD mice, myoblasts, and striatal cells were homogenized in cell extraction buffer containing 50 m M Tris-HCl (pH 7.4), 150 m M NaCl, 2 m M EDTA, 1% SDS, 0.5% NP-40, and 0.5% deoxycholate supplemented with protease and phosphatase inhibitors (Sigma), and the protein concentration was determined using a BCA protein assay (Pierce, USA). Equal amounts of protein (40 g) were loaded onto a 4-20% Tris-glycine gel (Invitrogen). The positive controls (cell lysates of COS1 cells transfected with the full-length PGC1 ␣ or NT-PGC1 ␣ ) for full-length PGC1 ␣ and NT-PGC1 ␣ were obtained from Calbiochem. After transfer, membranes were blocked for 1h at room temperature in Tris-buffered saline/Tween-20 (TBST) [50 m M Tris-HCl, 150 m M NaCl (pH 7.4), and 1% Tween-20] containing 5% nonfat dried milk. The membranes were incubated overnight at 4 ° C for PGC1 ␣ (1: 750; Calbiochem), uncoupling protein-1 (UCP-1) (1: 1,000; Calbiochem), and ␣ -tubulin (1: 10,000; Sigma). The membranes were then washed 3 times with TBST and incubated for 1h with HRP-conjugated secondary antibody, and the immunoreactive proteins were detected using a chemiluminescent substrate (Pierce). Protein expression was quantified using Scion Image software (NIH, USA).
HPLC Assay for cAMP
The cultured cells in each well were washed twice with phosphate-buffered saline (PBS) and then lysed by adding 150 l iceembedded acetonitrile followed by 75 l ice-cold sterile water. Lysates were centrifuged at 14,000 rpm and 4 ° C for 20 min. The supernatant was taken and diluted with an equal volume of water for HPLC assay. Fifty microliters of supernatant was applied to an HPLC system which comprises a Perkin Elmer M-250 binary LC pump, a Waters 717 plus autosampler, a Waters 2489 UV detector set at 260-nm wavelength, and an ESA 501 chromatography data process system. The gradient elution was built with 2 mobile phases at a rate of 1 ml/min through a 4.6 ! 250 mm, 5-m particle size TSK-GEL HPLC column. Mobile phase A contained 25 m M NaH 2 PO 4 and 100 mg/l tetrabutylammonium (pH 5.5), and mobile phase B contained 10%(v/v) acetonitrile mixed in a buffer of 200 m M NaH 2 PO 4 and 100 mg/l tetrabutylammonium (pH 4.0). Quantification was carried out using external standard calibration. The protein concentration was measured from the cell lysate.
Statistical Analysis
Data are presented as means 8 SEM. Statistical analysis was performed using GraphPad InStat software (GraphPad Software, Inc., San Diego, Calif., USA). The mean significant difference was determined using a 1-way ANOVA followed by a Tukey-Kramer post hoc multiple comparisons test or a 2-tailed Student's t test where appropriate. p ! 0.05 was considered statistically significant.
Results
The NT-PGC1 ␣ Protein Is Altered in HD Human and Mouse Brain
Using an antibody that recognizes both the full-length ('PGC1 ␣ ', ϳ 113 kDa) form and the spliced form ('NT-PGC1 ␣ ', ϳ 38 kDa) of PGC1 ␣ , we analyzed several samples of human brain, human myoblasts, and mouse brain ( fig. 1 a-d shows representative Western blots) and Q111 HD cells ( fig. 2 a) . The depletion of the full-length PGC1 ␣ protein was not consistent in human HD myoblasts and human and mouse HD brain samples ( fig. 1 a-d ) or in Q111 HD cells ( fig. 2 a) . However, the NT-PGC1 ␣ protein was prominently and consistently depleted in human HD myoblasts and mouse Q111 striatal cells ( fig. 1 b, 2 a) . In human brain, NT-PGC1 ␣ was depleted in grade 2 HD patients, while it was upregulated in grade 3 and grade 4 HD patients ( fig. 1 a) . NT-PGC1 ␣ was severely depleted in young HD transgenic mice, R6/2 mice, and N171-82Q mice, but it was upregulated in older phenotypic HD mice ( fig. 1 c, d ). It appears that the amount of NT-PGC1 ␣ rather than the amount of the full-length PGC1 ␣ variant is severely altered in HD human and mouse brain and in cultured HD myoblasts and striatal cells.
Elevated Intracellular cAMP Upregulates the Expression of Mitochondrial Genes and the NT-PGC1 ␣ Protein in HD Cells
PGC1 ␣ gene expression in HD cells can be significantly increased by cAMP [5] . We examined whether NT-PGC1 ␣ protein levels are affected by cAMP in Q111 HD cells. Consistent with earlier reports [7] , cAMP was greatly reduced in the Q111 cells versus Q7 cells ( fig. 2 b) . We treated Q7 and Q111 cells with forskolin + the phosphodiesterase inhibitor IBMX, which resulted in a 100-fold increase in cAMP levels in the Q7 and in a 710-fold increase in Q111 cells ( fig. 2 c) . This treatment also resulted in a significant increase in NT-PGC1 ␣ protein ( fig. 2 a) and mRNA ( fig. 2 d) levels in Q111 striatal cells. We also observed about a 3-fold increase in the protein expression of NT-PGC1 ␣ in Q111 cells treated with a cAMP analog (8-bromo-cAMP; data not presented), which corroborates the finding that the expression of NT-PGC1 ␣ is modulated by cAMP levels in these cells ( fig. 2 a, d) .
PGC1 ␣ acts upstream of nuclear respiratory factor NRF-1, which regulates the expression of nuclear-encod- ed mitochondrial genes such as mitochondrial transcription factor A (Tfam) and cytochrome c (Cyt c). We examined whether cAMP-mediated upregulation of NT-PGC1 ␣ in Q111 HD cells modulates the expression of its downstream targets. The mRNA expression levels of NRF-1 and Tfam were significantly downregulated in Q111 cells versus Q7 cells ( fig. 2 e, f) . Forskolin + IBMX produced similar changes in NRF-1 and Tfam mRNA expression ( fig. 2 e, f) . Similarly, treatment with 8-Br-cAMP (data not presented) also resulted in an increase in NRF- fig. 2 g) .
Cold Challenge Upregulated NT-PGC1 ␣ in Mouse BAT PGC1 ␣ mRNA is strongly induced in BAT by cold exposure [19] , resulting in enhanced mitochondrial heat generation during adaptive thermogenesis. We found that cold exposure of WT and R6/2 mice strongly increased NT-PGC1 ␣ protein levels rather than full-length PGC1 ␣ in BAT ( fig. 3 ) . Interestingly, the level of NT-PGC1 ␣ protein is also significantly upregulated in mice overexpressing PGC1 ␣ (no treatment or exposure to cold; fig. 3 ). It is known that PGC1 ␣ activates the thermogenic gene program of BAT through the control of UCP-1. We show here that UCP-1 protein levels are upregulated in concert with NT-PGC1 ␣ levels ( fig. 3 ).
Discussion
Reduced full-length PGC1 ␣ expression has been observed in transgenic mouse models of HD, in postmortem brain tissue from HD patients [5, 6, 20] , in muscle biopsies from HD patients, and in human HD myoblast cultures [21] . Our data are in line with this finding ( fig. 1 a-d) . All the studies on the role of PGC1 ␣ in HD to date have dealt with full-length PGC1 ␣ . Although splice variants of PGC1 ␣ have been reported earlier [10] [11] [12] [13] , their functional significance has not been elucidated. This is the first report to demonstrate that the amount of NT-PGC1 ␣ protein is severely altered in human HD brain, mouse HD models, and HD striatal neurons. We found that NT-PGC1 ␣ is significantly upregulated in HD cells by an increase in cAMP and by cold exposure in mouse BAT. An increase in NT-PGC1 ␣ was associated with upregulation of gene expression and increased mitochondrial protein content.
PGC1 ␣ has a complex structure with multiple domains. N-terminal leucine-rich domains (L2 and L3) mediate the interaction of PGC1 ␣ with the ligand-binding domains of nuclear receptors, whereas central and C-terminal domains mediate the interactions with PPAR ␥ , NRF-1, and other transcription factors. PGC1 ␣ also has a strong activation domain at the N-terminus, which interacts with a histone acetyltransferase complex, including steroid receptor coactivator-1 (SRC-1) and CREBbinding protein (CBP)/p300. Adjacent to the N-terminal domain is an inhibitory region that spans ϳ 200 amino acids. The short variant of PGC1 ␣ , NT-PGC1 ␣ , lacks this inhibitory domain, which implies that NT-PGC1 ␣ is likely a bona fide activator of gene expression; this is consistent with our data.
Regulation of PGC1 ␣ expression includes a 'positive feedback' loop where an increase in expression causes a further increase in its expression [22] . The transcriptional activity of PGC1 ␣ is also regulated by interaction with deacetylases such as SIRT1 [23, 24] , which increases its transcriptional activity, and by changes in PGC1 ␣ stability [23, 25] .
Further studies are required to elucidate whether an increase in NT-PGC1 ␣ protein content induced by cAMP in striatal cells or cold challenge in BAT was due to an increase in the stability of NT-PGC1 ␣ or an increase in expression of the PGC1 ␣ gene. It is not clear why the NT-PGC1 ␣ protein amount is strongly decreased in young animals that do not yet show a HD phenotype and at early stages of HD in humans but becomes strongly and consistently elevated in older HD animal models and in human brains with advanced HD stages. This may represent an adaptive increase in NT-PGC1 ␣ as an attempt to compensate for the increasing severity of the pathology and loss of mitochondria which occurs with increasing pathologic grades [26] . It has been shown that the major ATPbuffering and redistributing system in cells, i.e. the creatine kinase/phosphocreatine system, is severely reduced in human HD [27] . In theory, this should put more demand on the ATP-producing systems, such as glycolysis and mitochondria. The grade-dependent increases in NT-PGC1 ␣ levels in human postmortem brain could also be explained by the occurrence of inflammation and gliosis accompanying the death of neurons in later disease stages in which the glial population preferentially survives. The full-length PGC1 ␣ protein is localized in the nucleus and has a fast turnover (t 1/2 ! 30 min), while NT-PGC1 ␣ is predominantly cytoplasmic and relatively stable (t 1/2 1 7 h). It has recently been shown that PGC1 ␣ is primarily degraded in the nucleus via a ubiquitin proteasome pathway. It is evident that both isoforms are synthesized in HD tissues despite the presence of huntingtin on the PGC1 ␣ promoter. The accumulation of NT-PGC1 ␣ may therefore also be explained on the basis of its relatively higher stability and slower degradation, although further studies are required to investigate this phenomenon.
Conclusions
We showed here that the NT-PGC1 ␣ protein, a splice variant of ϳ 38 kDa, but not full-length PGC1 ␣ is severely and consistently altered in human HD brain, human HD myoblasts, mouse HD models, and HD striatal cells. The NT-PGC1 ␣ levels were significantly upregulated in HD cells and mouse brown fat by physiologically relevant stimuli that are known to upregulate PGC1 ␣ gene expression. This resulted in an increase in mitochondrial gene expression and Cyt c content. In summary, our data support the concept that NT-PGC1 ␣ is the major variant of PGC1 ␣ which is altered in HD brain and cells and that it is biologically active in controlling the expression of mitochondrial genes.
